In combination with a nonsteroidal aromatase inhibitor, abemaciclib was found to significantly increase progression free survival for patients with advanced HR+, HER2− breast cancer, relative to treatment with the aromatase inhibitor alone [49]. The gene discussed is CYP19A1; the disease is breast cancer.